Publications
PRECLINICAL PRESENTATIONS
American Society of Hematology Meeting 2007
Abstract Title: Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab-Sensitive and Rituximab-Resistant B-NHL Clones. Abstract No. 1402
Poster Session Info: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I, Board # 556-I
Saturday, December 8, 2007 - 5:30 PM
Abstract Title: Bcl-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells. Abstract No. 3464
Poster Session Info: Molecular Response Determinants, Board # 683-III
Monday, December 10, 2007 - 5:00 PM
Abstract Title: GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens. Abstract No. 1389
Poster Session Info: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I, Board # 543-I
Saturday, December 8, 2007 - 5:30 PM
Abstract Title: Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070. Abstract No. 2920
Poster Session Info: Chronic Myeloid Leukemia: Biology and Pathophysiology II, Board #139-III
Monday, December 10, 2007 - 5:00 PM
Abstract Title: The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy. Abstract No.806
Oral Session Info: Simultaneous Session: Molecular Pharmacology: Drug Resistance ,
Tuesday, December 11, 2007 - 7:45 AM
American Association for Cancer Research 2007
Abstract#4950 - BCL-2:BH3-only pro-apoptotic gene expression ratios correlate with in vitro sensitivity of primary MLL(+) infant acute lymphoblastic leukemia to small molecule pan-BCL-2 family inhibitor GX15-070. Alena Y. Zhang, Blaine W. Robinson, Jeffrey S. Barrett, Cheryl L. Willman, Carolyn A. Felix. Children's Hospital of Philadelphia, Philadelphia, PA, University of New Mexico, Albuquerque, NM.
American Society of Clinical Oncology 2006
GX15-070MS, a synthetic small molecule induces apoptosis in vitro and in vivo in chronic lymphocytic leukemia. J.E. Castro, C.E. Prada, S. Kitada, D. Contreras, J. Viallet, J.C. Reed, T.J. Kipps. Univ. of California San Diego, La Jolla, CA; The Burnham Institute, La Jolla, CA; Gemin X Biotechnologies, Malvern, PA.
American Society of Hematology Meeting 2006
Abstract #2502 - Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas. Blood, Volume 108, issue 11, November 16, 2006. Francisco J. Hernandez-Ilizaliturri, Seema Bhat, Arshad Iqbal, Scott Olejniczak, Joy Knight, Myron S. Czuczman. Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA; Internal Medicine, State University of New York at Buffalo/Catholic Health System, Buffalo, NY, USA.
Abstract #2523 - Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkins Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents. Blood, Volume 108, issue 11, November 16, 2006. Francisco J. Hernandez-Ilizaliturri, Arshad Iqbal, Naheed Alam, Seema Bhat, Scott Olejniczak, Joy Knight, Myron S. Czuczman. Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA; Internal Medicine, State University of New York at Buffalo/Catholic Health System, Buffalo, NY, USA.
Abstract #2532 - Inhibition of the Pan-Bcl-2 Family by the Small Molecule GX15-070 Induces Apoptosis in Mantle Cell Lymphoma (MCL) Cells and Enhances the Activity of Two Proteasome Inhibitors (NPI-0052 and Bortezomib), and Doxorubicin Chemotherapy. Blood, Volume 108, issue 11, November 16, 2006. Victor Y. Yazbeck, Georgios V. Georgakis, Yang Li, David McConkey, Michael Andreeff, Anas Younes. Lymphoma/Myeloma, M.D. Anderson Cancer Center, Houston, TX, USA; Cancer Biology, M.D. Anderson Cancer Center, Houston, TX, USA; Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract #2584 - Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhhibitor GX15-070 as a Novel Therapeutic Strategy in AML. Blood, Volume 108, issue 11, November 16, 2006. Julie C. Watt, Marina Konopleva, Rooha Contractor, Ismael Samudio, David Harris, Zeev Estrov, Jean Viallet, Michael Andreeff. Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Gemin X, Inc, Malvern, PA, USA.
Abstract #832 - Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma. Blood, Volume 108, issue 11, November 16, 2006. Gordon Shore, Mark Watson, Anne Roulston, Richard Marcellus, Nancy Steenart, Pierre Beauparlant, Sasmita Tripathy, Xavier Billot, Laurent Bélec, Giorgio Attardo, Mai Nguyen, Stephane Acoca, Enrico Purisima, Patricia Pérez-Galan, Dolors Colomer (Intr. by Jean Viallet). Research, Gemin X Biotechnologies, Inc, Montreal, QC, Canada; Biochemistry, McGill University, Montreal, QC, Canada; Computational Chemistry and Biology, Biotechnology Research Institute, Montreal, QC, Canada; Hematology, Hospital Clinic, University of Barcelona, Barcelona, Spain.
Abstract #3476 - The Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect. Blood, Volume 108, issue 11, November 16, 2006. Patricia Gomez-Bougie, Sophie Maïga, Catherine Pellat-Deceunynck, Sandrine Jouan, Regis Bataille, Martine Amiot (Intr. by Jean-Luc Harousseau). Cancer Research Department, INSERM U601, Nantes, France.
Abstract #4756 - In vitro and in vivo anti lymphoma effect of GX15-070 in mantle cell lymphoma. Blood, Volume 108, issue11, November16, 2006. Gwyn Bebb, Huong Muzik, Sophia Nguyen, Don Morris, Douglas A. Stewart. Translational Research Laboratory, Tom Baker Cancer Center, Calgary, AB, Canada; Department of Oncology, Tom Baker Cancer Center, Univ. of Calgary, Calgary, AB, Canada.
European Society for Medical Oncology 2006
Susceptibility of mantle cell lymphoma (MCL) and non-small cell lung cancer cell lines to targeting Bcl-2 using the small molecular inhibitor, GX15-070. D. Bebb, H. Muzik & Y. Ding. Tom Baker Cancer Center, Univ. of Calgary, Calgary, Canada.
American Society of Hematology Meeting 2005
Abstract #3368 - Pan-Bcl-2 Family Small Molecule Inhibitor GX015-070 (Gemin X, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations. Blood, Volume 106, issue 11, November 16, 2005. Jessicca M. Rege, Blaine W. Robinson, Manish Gupta, Jeffrey S. Barrett, Peter C. Adamson, Kathryn C. Behling, Andrew D. Bantly, Jonni S. Moore, Carolyn A. Felix. Div. of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Div. of Clinical Pharmacology & Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Pediatrics, University of Pennsylvania, Philadelphia, PA, USA.
Abstract #3372 - Inhibition of Bcl-2 Signaling by Small Molecule BH3 Inhibitor GX15-070 as a Novel Therapeutic Strategy in AML. Blood, Volume 106, issue 11, November 16, 2005. Rooha Contractor, Marina Konopleva, Ismael Samudio, Hagop Kantarjian, Michael Andreeff. Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract #1572 - Studies of the Bcl Inhibitor GX15-070 in Multiple Myeloma Demonstrate Substantial Pre-Clinical Activity. Blood, Volume 106, issue 11, November 16, 2005. A. Keith Stewart, Zhi Hua Li, Xiao Yan Wen, Jennifer Rauw, Latha Pathangey, P. Leif Bergsagel, Suzanne Trudel. Hematology-Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA; Hematology-Oncology, Princess Margaret Hospital, Toronto, ON, Canada; Multiple Myeloma Research Consoritum, New Canaan, CT, USA.
Abstract #1490 - The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib. Blood, Volume 106, issue 11, November 16, 2005. Patricia Perez Galan, Gael Roue, Neus Villamor, Elias Campo, Dolors Colomer. Hematopathology Unit, Department of Pathology and Hematology, Hospital Clinic. IDIBAPS, Barcelona, Spain.
return to top
PRECLINICAL PUBLICATIONS
Pre-clinical studies of the pan-Bcl Inhibitor Obatoclax (GX015-070) in Multiple Myeloma. Blood. 2007 Mar 1; [Epub ahead of print] Suzanne Trudel, Zhi Hua Li, Jennifer Rauw, Rodger E. Tiedemann, Xiao Yan Wen, A. Keith Stewart.
The BH3-mimetic GX15-070 synergizes with Bortezomib in Mantle Cell Lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007 Jan 16. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D.
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep. 2007 Feb;17(2):465-9. Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol. 2006 Dec;34(12):1663-9. Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, Coll-Mulet L, de Frias M, Domingo A, Pons G, Gil J.
Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in Cancer. Hematology 2005 (ASH Educational Program Book). 2005: 226-230. Gordon C. Shore and Jean Viallet.
return to top
CLINICAL PRESENTATIONS
American Society of Hematology 2007
Abstract Title: A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Abstract No. 2569
Poster Session Info: New Agents and Treatment Approaches in Non-Hodgkin Lymphoma, Board #759-II
Sunday, December 9, 2007 - 6:00 PM
Abstract Title: A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF). Abstract No. 3553
Poster Session Info: Myeloproliferative Syndromes: Therapy, Board #772-III
Monday, December 10, 2007 - 5:00 PM
Abstract Title: A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies. Abstract No. 892
Poster Session Info: Acute Myeloid Leukemias: Therapy, Excluding Transplantation I, Board #46-I
Saturday, December 8, 2007 - 5:30 PM
American Society of Hematology 2006
Abstract #2654 - A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by 24 Hour Infusion Every 2 Weeks to Patients with Myeloid Malignancies and Chronic Lymphocytic Leukemia (CLL). Blood, Volume 108, issue 11, November 16, 2006. Gautam Borthakur, Susan O'Brien, Farhad Ravandi-Kashani, Francis Giles, Aaron D. Schimmer, Jean Viallet, Hagop Kantarjian. Leukemia Department, MD Anderson Cancer Center, Houston, TX, USA; Princess Margaret Hospital, Toronto, ON, Canada; GeminX, Inc, Malvern, PA, USA.
European Hematology Association 2006
Small Molecule Pan-Bcl2 Family Inhibitor Obatoclax (GX15-070): Final Results of a Single Agent Phase I Trial in Patients with Refractory Chronic Lymphocytic Leukemia (CLL). Susan O'Brien1, David Claxton2 , Michael Crump3, Stefan Faderl1, Thomas Kipps4 , Michael Keating1, Bruce Cheson5. 1Leukemia Department, MD Anderson Cancer Center, Houston, TX; 2Hershey Medical Center; 3Princess Margaret Hospital Toronto, ON; 4Division of Hematology-Oncology, University of California San Diego; 5Georgetown University, Washington DC.
Chemotherapy Foundation Symposium 2006
Small Molecule Pan-Bcl2 Family Inhibitor Obatoclax (GX15-070): Overview of Clinical Phase I Study Results. Susan O'Brien1, John Marshall2, Jean Viallet3, Hagop Kantarjian1. 1 Leukemia Department, MD Anderson Cancer Center, Houston, TX; 2 Georgetown University, Washington DC; 3 Gemin X Inc, Malvern, PA.
American Society of Clinical Oncology 2006
A Phase I Study of the Pan-Bcl2 Family Inhibitor GX15-070, Administered as a 3-hour Weekly Infusion in Patients with Refractory Solid Tumors or Lymphomas. K Alam Firozvi1, L Siu2, D Mendelson3, J Marshall1, M Maclean2, J Hwang1, S Malik1, N Hansen1 and J Kuruvilla2. Georgetown University1, Washington DC; Princess Margaret Hospital2, Toronto, ON; Premiere Oncology of Arizona3, Scottsdale, AZ.
American Society of Hematology 2005
Abstract #446 - A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, Volume 106, issue 11, November 16, 2005. Susan O'Brien, Thomas J. Kipps, Stefan Faderl, Michael Crump, Michael J. Keating, Blanche Anderson, Claudia Soho, Jan Bole, Ruth Turner, Jean Viallet, Bruce D. Cheson. Leukemia, MD Anderson Cancer Center, Houston, TX, USA; Div. of Hematology-Oncology, Univ. of California San Diego, La Jolla, CA, USA; Princess Margaret Hospital, Toronto, ON, Canada; GeminX, Inc., Malvern, PA, USA; Georgetown University Hospital, Washington, DC, USA.
return to top
CLINICAL PUBLICATIONS
None at this point
